| Reason for the Action |
The presence of a glass particle was reported in a vial of Hydrocortisone (as sodium succinate) 100 mg powder for injection vial. The contaminant was identified as a single glass fragment measuring approximately 8.88 × 6.13 × 1.04 mm length x width x height.
The observed glass particle will not pass through the standard injection needle. Although the particle is relatively large and likely to be detected during preparation, the possibility of fragmentation into smaller particles cannot be excluded.
Given the intravenous route of administration, if smaller fragments were inadvertently administered, potentially serious consequences could include vascular injury or obstruction and inflammatory reactions. Intramuscular administration could result in local mechanical tissue injury, pain, inflammation, tissue damage, or a foreign-body reaction.
This action does not affect any other batches of CIPLA HYDROCORTISONE (as sodium succinate) 100 mg powder for injection vial or any other products distributed by Echo.
To date, no adverse events have been reported within Australia. |